A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicidesVAN HERREWEGE, Yven; VANHAM, Guido; MICHIELS, Jo et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 10, pp 3684-3689, issn 0066-4804, 6 p.Article

Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART TrialPIRILLO, Maria; PALMISANO, Lucia; VELLA, Stefano et al.AIDS research and human retroviruses. 2010, Vol 26, Num 5, pp 541-545, issn 0889-2229, 5 p.Article

Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitorFERRIS, Robert G; HAZEN, Richard J; SHORT, Steven A et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 10, pp 4046-4051, issn 0066-4804, 6 p.Article

Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase InhibitorLAI, Ming-Tain; MUNSHI, Vandna; TOUCH, Sinoeun et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 6, pp 2424-2431, issn 0066-4804, 8 p.Article

Reverse Transcriptase Inhibitors as Potential Colorectal MicrobicidesHERRERA, Carolina; CRANAGE, Martin; MCGOWAN, Ian et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 5, pp 1797-1807, issn 0066-4804, 11 p.Article

How common is the non-nucleoside reverse transcriptase inhibitor mutation E138K in clinical practice?BRADSHAW, Daniel; MANDALIA, Sundhiya; NELSON, Mark et al.The Journal of infection. 2011, Vol 63, Num 2, pp 172-173, issn 0163-4453, 2 p.Article

Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance : evidence of transmitted resistance in rural South AfricaBARTH, Roos E; WENSING, Annemarie M; TEMPELMAN, Hugo A et al.AIDS (London). 2008, Vol 22, Num 16, pp 2210-2212, issn 0269-9370, 3 p.Article

Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytesRODRIGUEZ DE LA CONCEPCION, M. Luisa; YUBERO, Pilar; DOMINGO, Joan C et al.Antiviral therapy (London). 2005, Vol 10, Num 4, pp 515-526, issn 1359-6535, 12 p.Article

SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase InhibitorsBALLANA, Ester; BADIA, Roger; TERRADAS, Gerard et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 8, pp 4804-4813, issn 0066-4804, 10 p.Article

Topical Nonnucleoside Reverse Transcriptase Inhibitor MC 1220 Partially Prevents Vaginal RT-SHIV Infection of MacaquesSTOLTE-LEEB, Nicole; LODDO, Roberta; STAHL-HENNIG, Christiane et al.AIDS research and human retroviruses. 2011, Vol 27, Num 9, pp 933-943, issn 0889-2229, 11 p.Article

Long term adverse effects related to nucleoside reverse transcriptase inhibitors: Clinical impact of mitochondrial toxicityMAAGAARD, Anne; KVALE, Dag.Scandinavian journal of infectious diseases. 2009, Vol 41, Num 11-12, pp 808-817, issn 0036-5548, 10 p.Article

In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survivalKOSMISKI, Lisa A; MILLER, Heidi L; KLEMM, Dwight J et al.Antiviral therapy (London). 2006, Vol 11, Num 2, pp 187-195, issn 1359-6535, 9 p.Article

Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondriaMORRIS, Gerald W; LACLAIR, Darcy D; MCKEE, Edward E et al.Antiviral therapy (London). 2010, Vol 15, Num 4, pp 495-505, issn 1359-6535, 11 p.Article

Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitorsAFONSO, Philippe V; MEKAOUCHE, Mourad; HERMINE, Olivier et al.Blood. 2010, Vol 116, Num 19, pp 3802-3808, issn 0006-4971, 7 p.Article

Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitorsHILL, Shawn A; LLOYD, Patricia A; MCDONALD, Shannon et al.The Journal of infectious diseases. 2003, Vol 188, Num 3, pp 424-427, issn 0022-1899, 4 p.Article

Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapyMOORE, Jeff D; ACOSTA, Edward P; JOHNSON, Victoria A et al.Antiviral therapy (London). 2007, Vol 12, Num 6, pp 981-986, issn 1359-6535, 6 p.Article

Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: A phase 1 studyGEWURZ, Benjamin E; JACOBS, Mark; PROPER, Jo Ann et al.The Journal of infectious diseases. 2004, Vol 190, Num 11, pp 1957-1961, issn 0022-1899, 5 p.Article

Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited SettingsHILL, Andrew; MCBRIDE, Angela; SAWYER, A. William et al.The Journal of infectious diseases. 2013, Vol 207, issn 0022-1899, S78-S84, SUP2Article

Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase InhibitorsGARCIA-LERMA, J. Gerardo; AUNG, Wutyi; YEN-CHIN LIN, Carol et al.Journal of virology. 2011, Vol 85, Num 13, pp 6610-6617, issn 0022-538X, 8 p.Article

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results (The Advanz Trial): A Randomized, Controlled TrialMIRO, José M; MANZARDO, Christian; DE LAZZARI, Elisa et al.AIDS research and human retroviruses. 2010, Vol 26, Num 7, pp 747-757, issn 0889-2229, 11 p.Article

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitorsTAMBUYZER, Lotke; AZIJN, Hilde; RIMSKY, Laurence T et al.Antiviral therapy (London). 2009, Vol 14, Num 1, pp 103-109, issn 1359-6535, 7 p.Article

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicityRITCHIE, Marylyn D; HAAS, David W; STERLING, Timothy R et al.Clinical infectious diseases. 2006, Vol 43, Num 6, pp 779-782, issn 1058-4838, 4 p.Article

Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimenLANDAY, Alan L; SPRITZLER, John; KESSLER, Harold et al.The Journal of infectious diseases. 2003, Vol 188, Num 10, pp 1444-1454, issn 0022-1899, 11 p.Article

Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to SwitchJOHNSTON, Victoria; COHEN, Karen; WIESNER, Lubbe et al.The Journal of infectious diseases. 2014, Vol 209, Num 5, pp 711-720, issn 0022-1899, 10 p.Article

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor+protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trialSOULIE, Cathia; ASSOUMOU, Lambert; MARCELIN, Anne-Geneviève et al.AIDS (London). 2009, Vol 23, Num 12, pp 1605-1608, issn 0269-9370, 4 p.Article